Levetiracetam Clearance Time
In adults with normal renal function, levetiracetam has an elimination half-life of approximately 6-8 hours, with a renal clearance of 0.6 mL/min/kg and total body clearance of 0.96 mL/min/kg 1.
Pharmacokinetic Parameters
The clearance characteristics of levetiracetam are straightforward:
- Half-life: 7 ± 1 hour in adults with normal renal function 1
- Renal clearance: 0.6 mL/min/kg 1
- Total body clearance: 0.96 mL/min/kg 1
- Renal excretion: 66% of the dose is excreted unchanged in urine 1
The drug achieves steady-state within 24-48 hours of twice-daily dosing 1. Peak plasma concentrations occur approximately 1 hour after oral administration in fasted subjects 1.
Mechanism of Elimination
Levetiracetam elimination occurs primarily through renal excretion via glomerular filtration with subsequent partial tubular reabsorption 1. Only 34% undergoes metabolism, which occurs primarily in blood through enzymatic hydrolysis of the acetamide group—not through hepatic cytochrome P450 pathways 1. This makes levetiracetam clearance directly correlated with creatinine clearance 1.
Special Population Considerations
Elderly patients experience prolonged clearance due to age-related decline in renal function. The half-life extends to approximately 10-11 hours, with total body clearance decreasing by 38% compared to younger adults 1.
Pediatric patients (ages 4-12 years) demonstrate faster clearance, with a half-life of approximately 5-7 hours 1. Body weight-adjusted clearance is approximately 40% higher than in adults 1.
Renal impairment significantly impacts clearance:
- Mild impairment (CrCl 50-80 mL/min): 40% reduction in clearance
- Moderate impairment (CrCl 30-50 mL/min): 50% reduction
- Severe impairment (CrCl <30 mL/min): 60% reduction
- End-stage renal disease: 70% reduction 1
During standard 4-hour hemodialysis, approximately 50% of levetiracetam is removed from the body 1.
Clinical Implications
Dose adjustments are mandatory in renal impairment but unnecessary in hepatic disease, as the drug is not hepatically metabolized 1. The favorable pharmacokinetic profile—including minimal protein binding (<10%), linear kinetics across the therapeutic dose range (500-5000 mg), and lack of hepatic metabolism—makes levetiracetam relatively straightforward to dose 1.
Augmented renal clearance (ARC) in critically ill patients can increase clearance up to 6.5 L/h (versus 3.8 L/h in healthy individuals), potentially requiring higher doses (at least 1500 mg twice daily) to maintain therapeutic levels 2.
The drug does not undergo autoinduction, and its clearance remains consistent with repeated administration 1.